Sodium oligomannurarate

Drug Profile

Sodium oligomannurarate

Alternative Names: GV-971; Sodium oligo-mannurarate

Latest Information Update: 13 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Shanghai Green Valley Pharmaceutical
  • Class Mannans; Nootropics; Oligosaccharides
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 01 Nov 2016 Shanghai Greenvalley Pharmaceutical initiates a phase I bioavailability trial in Healthy volunteers in China (PO, Capsule) (NCT02986529)
  • 08 Aug 2016 Sodium Oligomannurarate is still in phase III trials for Alzheimer's disease in China (PO) (NCT02293915)
  • 01 Apr 2014 Phase-III clinical trials in Alzheimer's disease in China (PO) (NCT02293915)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top